Eli Lilly and Co.

18 sie 2026, 23:06 UTC

Eli Lilly shares are lower in after-market hours amid scrutiny over its planned acquisition of Sangamo's gene therapy technologies from Genentech and others.

17 sie 2026, 23:06 UTC

Eli Lilly and Co. shares showed little change in after-market trading, remaining within a narrow range since Monday's close.

14 sie 2026, 20:02 UTC

Eli Lilly shares are lower as analysts raise concerns after a revenue miss and lower adjusted EPS guidance, despite U.K. approval for its weight loss drug.

13 sie 2026, 19:36 UTC

Eli Lilly shares are lower as Investor Business Daily's SwingTrader sells its position, raising concerns about investor sentiment and pricing strategy for GLP-1 medications.

12 sie 2026, 23:01 UTC

Eli Lilly filed six lawsuits against U.S. companies over unauthorized sales of its obesity drug retatrutide. Shares are lower in after-market trading.

11 sie 2026, 19:36 UTC

Eli Lilly's stock is declining despite UK approval of its GLP-1 pill for diabetes and weight management, amid cautious investor sentiment following recent gains.

10 sie 2026, 23:16 UTC

Eli Lilly and Co shares are lower in after-market hours, following a narrow trading range since Monday's close and reflecting broader market trends.

8 sie 2026, 00:02 UTC

Eli Lilly shares are higher in after-market trading following FDA filing plans for retatrutide, a potential competitor in the weight-loss market.

7 sie 2026, 19:16 UTC

Eli Lilly shares are lower today, despite an increase in TRx sales to 34,219 from 29,388 last week. The stock remains within its one-month range.

6 sie 2026, 19:16 UTC

Eli Lilly shares rose as analysts raised price targets, reflecting strong quarterly results and demand growth for its obesity drugs.

5 sie 2026, 23:42 UTC

Eli Lilly reported second-quarter revenue of $23 billion, raising its full-year guidance to $85 billion to $87 billion. Shares are higher in after-market trading.

4 sie 2026, 23:02 UTC

Eli Lilly shares are higher in after-market trading, driven by a broader market rally and optimism surrounding potential oil supply agreements.

3 sie 2026, 20:03 UTC

Eli Lilly's shares are declining amid negative sentiment despite expanding access to its obesity drug retatrutide and receiving FDA designation for olomorasib.

31 lip 2026, 23:06 UTC

Eli Lilly and Co shares are higher in after-market trading, though they remain below their 20-day moving average by 2.91%. No specific news was identified.

30 lip 2026, 21:01 UTC

Eli Lilly shares are higher in after-market trading, recovering from an earlier dip. Broader market sentiment remains positive amid geopolitical tensions and inflation concerns.

29 lip 2026, 23:26 UTC

Eli Lilly and Co shares are lower in after-market hours amid unusual trading activity. Broader market volatility follows the Federal Reserve's interest rate decision.

28 lip 2026, 22:06 UTC

Eli Lilly shares are lower in after-market hours, with no specific news identified. Broader market trends may be impacting sentiment following declines in the Nikkei 225 Index.

27 lip 2026, 23:16 UTC

Eli Lilly and Co shares are lower in after-market hours, continuing a decline since Monday's close amid a broader market downturn. No specific news was identified.

24 lip 2026, 23:41 UTC

Eli Lilly and Co shares declined in after-market trading, experiencing notable fluctuations without any specific news to explain the price action.

23 lip 2026, 10:06 UTC

Eli Lilly shares are lower in pre-market trading, nearing the $1074–$1003 support zone. Broader market declines coincide with traders awaiting the ECB's interest rate decision.

22 lip 2026, 23:16 UTC

Eli Lilly acquires ATAI for $2.8 billion, entering the psychedelic medicine sector. Shares are higher in after-market trading following the announcement.

21 lip 2026, 20:07 UTC

Eli Lilly is higher today, supported by overall market strength and plans to defend against a lawsuit from Novo Nordisk over its weight-loss drugs.

20 lip 2026, 23:16 UTC

Eli Lilly's shares are roughly flat in after-market trading, amid rising treasury yields and geopolitical tensions affecting interest-sensitive sectors like pharmaceuticals.